Monitoring brain-derived tau levels in acute ischemic stroke patients
PRecisiOn Medicine In StrokE Study on the Evolution of Plasma Brain-Derived Tau in 100 Patients With Acute Ischemic Stroke
This study is testing how brain-derived tau levels change in stroke patients over 48 hours to see if it can help understand their condition and improve treatment decisions.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Ludwig-Maximilians - University of Munich Academic / other |
| Locations | 1 site (Munich, Bavaria) |
| Trial ID | NCT06121336 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the evolution of plasma brain-derived tau (BD-tau) levels in patients diagnosed with acute ischemic stroke. By measuring BD-tau levels every hour from admission to 48 hours post-onset, the study seeks to understand how these levels correlate with infarct progression and patient outcomes. The research builds on previous findings that suggest BD-tau is a sensitive biomarker for brain injury, potentially offering insights into the dynamics of stroke progression and aiding in therapeutic decision-making. The study will include patients presenting within 9 hours of symptom onset with confirmed large- or medium-vessel occlusion.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with a clinical diagnosis of acute ischemic stroke and large- or medium-vessel occlusion confirmed by imaging.
Not a fit: Patients with a history of recent brain injury, severe renal dysfunction, or pre-stroke disability may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the ability to monitor stroke progression and improve patient outcomes through better-informed therapeutic decisions.
How similar studies have performed: Previous studies have indicated the potential of blood-based biomarkers like BD-tau in monitoring brain injury, suggesting a promising avenue for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * clinical diagnosis of acute ischemic stroke * presentation within 9 hours of symptom onset * large- or medium-vessel occlusion (i.e. an occlusion of the ICA, MCA \[segments M1-M4\], ACA \[segments A1-A3\], basilar artery, or PCA \[segments P1 to P3\]) confirmed by CT or MRI angiography * at least 18 years of age * written informed consent Exclusion Criteria: * CT or MRI showing intracranial hemorrhage upon admission * A history of ischemic stroke, subarachnoid hemorrhage, intracerebral hemorrhage, subdural hematoma, epidural hematoma, CNS tumor, meningitis, or encephalitis within the last three months * severe renal dysfunction (eGFR \< 30ml/min/1.73m2) * dementia * pre-stroke disability defined as a premorbid modified Rankin Scale score \> 1
Where this trial is running
Munich, Bavaria
- LMU University hospital, LMU Munich — Munich, Bavaria, Germany (Recruiting)
Study contacts
- Study coordinator: Steffen Tiedt, MD PhD
- Email: steffen.tiedt@med.uni-muenchen.de
- Phone: +4989440046046
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.